IQVIA CEO exercises 77,592 rights, sells shares around $220

Q: How many shares did the IQV CEO own after the transactions?

He beneficially owned 807,163 shares directly after the reported transactions.

Q: Does the insider have any indirect ownership in IQV?

Yes. He reported 543,302 shares held indirectly by a trust.

Q: What derivative security was exercised by the IQV CEO?

A stock appreciation right covering 77,592 underlying shares, with a $59.90 exercise price and expiring on 02/02/2026.

IQVIA (IQV) insider transaction: On 10/29/2025, Chairman, Chief Executive Officer & President Ari Bousbib exercised stock appreciation rights for 77,592 shares at an exercise price of $59.90, then sold shares in multiple open‑market transactions.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

IQVIA (IQV) insider transaction: On 10/29/2025, Chairman, Chief Executive Officer & President Ari Bousbib exercised stock appreciation rights for 77,592 shares at an exercise price of $59.90, then sold shares in multiple open‑market transactions. The reported weighted average sale prices ranged from $216.70 to $222.27 across the disclosed trade batches.

Following these transactions, Bousbib beneficially owned 807,163 shares directly. He also reported 543,302 shares held indirectly by a trust.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 10 txns

Insider BOUSBIB ARI

Role See Remarks

Sold 56,557 shs ($12.46M)

Approx. gross sale proceeds $12.46M

Approx. exercise cost $4.65M

Type	Security	Shares	Price	Value
Exercise	Stock Appreciation Right	77,592	$59.90	$4.65M
Exercise	Common Stock	77,592	$59.90	$4.65M
Sale	Common Stock	800	$217.58	$174K
Sale	Common Stock	7,315	$218.32	$1.60M
Sale	Common Stock	13,741	$219.29	$3.01M
Sale	Common Stock	4,600	$220.11	$1.01M
Sale	Common Stock	26,128	$221.31	$5.78M
Sale	Common Stock	3,973	$221.97	$882K
Disposition	Common Stock	21,035	$220.96	$4.65M
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Appreciation Right — 50,000 contracts (Direct); Common Stock — 807,163 shares (Direct); Common Stock — 543,302 shares (Indirect, By Trust)

Footnotes (8)

F1. Represents the exercise of stock appreciation rights expiring on February 2, 2026.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.70 to $217.70, inclusive.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.73 to $218.70, inclusive.
F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.73 to $219.66, inclusive.
F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.74 to $220.62, inclusive.
F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.77 to $221.72, inclusive.
F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.82 to $222.27, inclusive.
F8. Shares held in Orohena Trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IQV (IQVIA) disclose in this Form 4?

Ari Bousbib exercised stock appreciation rights for 77,592 shares at $59.90 and sold shares in multiple transactions.

What were the sale price ranges reported for IQV shares?

Weighted average prices were reported with ranges from $216.70 to $222.27 across the trade batches.

How many shares did the IQV CEO own after the transactions?

He beneficially owned 807,163 shares directly after the reported transactions.

Does the insider have any indirect ownership in IQV?

Yes. He reported 543,302 shares held indirectly by a trust.

What derivative security was exercised by the IQV CEO?

A stock appreciation right covering 77,592 underlying shares, with a $59.90 exercise price and expiring on 02/02/2026.

When did the earliest reported transaction occur?

The earliest transaction date reported was 10/29/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/31/2025 - 05:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOUSBIB ARI

(Last)

(First)

(Middle)

C/O IQVIA HOLDINGS INC.

2400 ELLIS ROAD

(Street)

DURHAM

27703

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IQVIA HOLDINGS INC. [ IQV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/29/2025		M		77,592⁽¹⁾	A	$59.9	884,755	D
Common Stock	10/29/2025		S		800⁽¹⁾	D	$217.58⁽²⁾	883,955	D
Common Stock	10/29/2025		S		7,315⁽¹⁾	D	$218.32⁽³⁾	876,640	D
Common Stock	10/29/2025		S		13,741⁽¹⁾	D	$219.29⁽⁴⁾	862,899	D
Common Stock	10/29/2025		S		4,600⁽¹⁾	D	$220.11⁽⁵⁾	858,299	D
Common Stock	10/29/2025		S		26,128⁽¹⁾	D	$221.31⁽⁶⁾	832,171	D
Common Stock	10/29/2025		S		3,973⁽¹⁾	D	$221.97⁽⁷⁾	828,198	D
Common Stock	10/29/2025		D		21,035⁽¹⁾	D	$220.96	807,163	D
Common Stock								543,302	I	By Trust⁽⁸⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Appreciation Right	$59.9	10/29/2025		M			77,592	02/02/2020	02/02/2026	Common Stock	77,592	$59.9	50,000	D

Explanation of Responses:

1. Represents the exercise of stock appreciation rights expiring on February 2, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.70 to $217.70, inclusive.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.73 to $218.70, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.73 to $219.66, inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.74 to $220.62, inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.77 to $221.72, inclusive.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.82 to $222.27, inclusive.

8. Shares held in Orohena Trust.

Remarks:

Chairman, Chief Executive Officer & President

	/s/ Matthew Gilmartin, Attorney-in-Fact for Ari Bousbib	10/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR